Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 7/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PNP | P00491 | 1/20 | 0.33 |
| ▸ | ADK | P55263 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14929264 | 0.89 | SLC5A2 (0.44) | SLC5A2SLC5A1 | |
| SCHEMBL16781795 | 0.89 | SLC5A2 (0.44) | SLC5A2SLC5A1 | |
| SCHEMBL18573960 | 0.89 | SLC5A2 (0.44) | SLC5A2SLC5A1 | |
| SCHEMBL14853668 | 0.89 | SLC5A2 (0.44) | SLC5A2SLC5A1 | |
| SCHEMBL21082362 | 0.86 | SLC5A2 (0.36) | SLC5A2TSHRSLC5A1HTTSMN1; SMN2 | |
| SCHEMBL17384649 | 0.85 | TSHR (0.36) | SLC5A2TSHRSLC5A1HTTSMN1; SMN2 | |
| SCHEMBL17211429 | 0.82 | TSHR (0.40) | SLC5A2TSHRSLC5A1SMN1; SMN2HSD17B10 | |
| SCHEMBL14946151 | 0.81 | FBP1 (0.49) | — | |
| SCHEMBL14945996 | 0.81 | SLC5A1 (0.32) | SLC5A2TSHRSLC5A1HTTSMN1; SMN2 | |
| SCHEMBL15249044 | 0.81 | SLC5A1 (0.32) | SLC5A2TSHRSLC5A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | SLC5A2 2756/4885TSHR 2428/4885SLC5A1 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.